Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

University of Western Ontario

$25,000.00

Examination of AcpS in the survival of S. aureus

EF 2014-15

Résumé
Bacteria are small single cell organisms. Most bacteria are harmless and contribute to normal functioning of the body. Infectious bacteria on the other hand (for example, Staphylococcus aureus) can cause illness, which can be severe if left untreated. Bacterial infections can be treated with antibiotics however, with their increased use, bacteria have developed strategies to evade death by antibiotics, called drug resistance. New types of antibiotics are needed to combat these drug-resistant bacteria.A solid understanding of how bacteria function is required In order to develop new antibiotics. By examining mechanisms that are important to the survival of bacteria, one can devise strategies to turn these mechanisms off and cause bacterial death. The proposed project aims to explore the role of the protein, AcpS, and how it contributes to survival. AcpS is critical to the synthesis of fatty acids, which are a vital structural component of the bacteria and important for their survival.DeNovaMed Inc. is a biotechnology company aimed at developing new antibiotics that target AcpS. They have developed a collection of compounds that are effective at killing bacteria, but are seeking validation that these compounds actually target AcpS. In the proposed project, we will develop a system to increase the levels of AcpS in the bacteria S. aureus. We will then treat these cells with a selection of DeNovaMed's compounds to determine whether increased levels of AcpS allow the bacteria to survive following treatment. This project will contribute to our ongoing efforts to study bacterial biology and will point to potential methods by which we can develop new antibiotics to treat infection.
Programme
Engage Grants Program
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
470317-2014
Name nom
Heinrichs, David
Department département
Microbiology and Immunology
Organization id
36
Institution établissement
University of Western Ontario
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2014
Competition year année de concours
2014
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
5201
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Bacteriology
Research subject fr
Bactériologie
Partie
1
Nb partie
1
Application title
Examination of AcpS in the survival of S. aureus
Keyword
NSERC
Application summary
Bacteria are small single cell organisms. Most bacteria are harmless and contribute to normal functioning of the body. Infectious bacteria on the other hand (for example, Staphylococcus aureus) can cause illness, which can be severe if left untreated. Bacterial infections can be treated with antibiotics however, with their increased use, bacteria have developed strategies to evade death by antibiotics, called drug resistance. New types of antibiotics are needed to combat these drug-resistant bacteria.A solid understanding of how bacteria function is required In order to develop new antibiotics. By examining mechanisms that are important to the survival of bacteria, one can devise strategies to turn these mechanisms off and cause bacterial death. The proposed project aims to explore the role of the protein, AcpS, and how it contributes to survival. AcpS is critical to the synthesis of fatty acids, which are a vital structural component of the bacteria and important for their survival.DeNovaMed Inc. is a biotechnology company aimed at developing new antibiotics that target AcpS. They have developed a collection of compounds that are effective at killing bacteria, but are seeking validation that these compounds actually target AcpS. In the proposed project, we will develop a system to increase the levels of AcpS in the bacteria S. aureus. We will then treat these cells with a selection of DeNovaMed's compounds to determine whether increased levels of AcpS allow the bacteria to survive following treatment. This project will contribute to our ongoing efforts to study bacterial biology and will point to potential methods by which we can develop new antibiotics to treat infection.